Search Results
Your search for ,CNS matches 915 pages
Showing 1 - 50Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups
An exploratory overall survival analysis of the phase III FLAURA2 trial confirmed the overall survival benefit of adding osimertinib to chemotherapy in patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) not previously treated for advanced...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
Vorasidenib in IDH1/2-Mutant Low-Grade Glioma
As reported in The Lancet Oncology by Cloughesy et al, vorasidenib was associated with improvement in some secondary and exploratory outcomes vs placebo in the phase III INDIGO trial in patients with residual or recurrent IDH1-mutant or IDH2-mutant low-grade glioma. Initial reports at second...
Experts Outline Roadmap for Clinical Implementation of AI in Pediatric CNS Tumor Management
A subcommittee of the RAPNO (Response Assessment in Pediatric Neuro-Oncology) consortium that is focused on artificial intelligence (AI-RAPNO) has released guidance on the responsible implementation of AI in pediatric neuro-oncology in the form of a two-part policy review published in The Lancet...
Investigational Antibody-Drug Conjugate in Previously Treated SCLC
About 13% of all lung cancers in the United States are small cell lung cancer (SCLC), and approximately 87% are non–small cell lung cancer (NSCLC). Together, these lung cancers are the second most common cancer diagnosed in both men and women, excluding skin cancer. Usually a very aggressive...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib/Chemotherapy in EGFR-Positive NSCLC
The combination of osimertinib plus chemotherapy led to a median overall survival of 47.5 months compared with 37.6 months with osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who had not received prior treatment for advanced disease, according to...
Dose-Intensified Proton Therapy for Newly Diagnosed Glioblastoma
Dose intensification of proton radiation therapy led to improved overall survival for patients with newly diagnosed glioblastoma, according to findings from a cohort of the phase II NRG-BN001 trial, which were presented as late-breaking research during the 2025 American Society for Radiation...
Association of TERT Expression With Outcomes in Meningioma
In an analysis reported in The Lancet Oncology by Gui et al in the International Consortium on Meningiomas, TERT expression in meningiomas was found to be associated with poorer progression-free survival. Study Details The multi-institutional cohort study involved retrospectively collected data...
Osimertinib Plus Chemotherapy Significantly Prolongs Overall Survival in EGFR-Mutated Advanced NSCLC
The combination of the EGFR-targeting tyrosine kinase inhibitor osimertinib with platinum-based chemotherapy significantly improved overall survival as a first-line treatment for patients with EGFR-mutated, advanced, non–small cell lung cancer (NSCLC) compared with osimertinib monotherapy,...
Proton Craniospinal Irradiation for Leptomeningeal Metastasis in Lung or Breast Cancer
In an interim analysis of a phase II trial reported in JAMA Oncology, Yang et al found that proton craniospinal irradiation (pCSI) improved central nervous system (CNS) progression-free survival vs photon involved-field radiotherapy (IFRT) in patients who have breast cancer or non–small cell lung...
Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia
In a phase I, first-in-human trial of nearly 50 patients with relapsed or refractory B-cell malignancies, the orally administered, small molecule degrader bexobrutideg (NX-5948) was reported to be well tolerated, including in those with a longer duration of treatment and higher doses. Clinical...
Is TBI Associated With Malignant Brain Tumors?
The results of a retrospective cohort study published in JAMA Network Open revealed an association between having a history of moderate to severe traumatic brain injury (TBI) and the risk of developing malignant brain tumors in adult civilians from the United States. Marini et al confirmed the...
How a Novel Coaching Intervention Is Building Resilience and Hope in Adolescents and Young Adults With Advanced Cancer
Each year, nearly 90,000 adolescents and young adults (AYAs; aged 15–39) are diagnosed with cancer, and approximately 9,300 die of the disease.1 And although the 5-year survival rate among these young patients is approaching 80%, it lags behind that of the pediatric population, whose 5-year...
EGFR-Mutated NSCLC: Continuing Osimertinib Plus Chemotherapy Through Disease Progression Improves PFS
A new analysis from the COMPEL trial showed that patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who experienced non–central nervous system (CNS) disease progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based...
Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test
A novel, multianalyte test has been developed to identify central nervous system cancers from small samples of cerebrospinal fluid (CSF). In findings published in Cancer Discovery, the study authors reported that the test, called CSF-BAM, achieved a sensitivity of 81% and a specificity of 100%....
Glioblastoma: Dual Immunotherapy Plus Radiotherapy in Newly Diagnosed MGMT-Unmethylated Disease
The combination of ipilimumab and nivolumab plus radiation therapy did not lead to an improvement in progression-free survival compared with radiation therapy and temozolomide for patients with newly diagnosed MGMT-unmethylated glioblastoma, according to phase II results of the NRG-BN007 trial...
Protease Activator Approved by the FDA for Diffuse Midline Glioma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to dordaviprone (Modeyso) a protease activator, for adult and pediatric patients aged 1 year and older with diffuse midline glioma harboring an H3 K27M mutation who have progressive disease after prior therapy. This...
Pediatric Gliomas: Early Research on Targeted Therapies
A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9% of children with glioma, the most common type of pediatric brain tumor, have alterations in the fibroblast growth factor receptor (FGFR) family of proteins, and these gliomas may be sensitive to...
Pediatric CNS Tumors: Long-Term Survival and Cure Fraction Estimates
As reported in The Lancet Oncology by Hoogendijk et al, the EUROCARE-6 population-based study has provided long-term survival rates and cure fraction estimates for pediatric patients with central nervous system (CNS) tumors across 31 European countries. Study Details The study involved data from...
Case 3: High-Grade Astrocytoma
This is Part 3 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade glioma. The...
Case 2: Low-Grade Glioma
This is Part 2 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade glioma. The...
Case 1: Low-Grade Oligodendroglioma
This is Part 1 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade...
Patritumab Deruxtecan Shows Efficacy in Leptomeningeal Metastases From Solid Tumors
The HER3-directed antibody-drug conjugate patritumab deruxtecan demonstrated clinical efficacy in treating patients with leptomeningeal metastatic disease of solid tumors, according to findings from a cohort of the phase II TUXEDO-3 trial. Researchers were also encouraged by the intracranial...
Subsequent Neoplasm Risk Among Childhood Cancer Survivors: Effect of BMI and Physical Activity
In a study reported in JAMA Oncology, Joffe et al examined the association of high body mass index (BMI) and low physical activity with increased risk of subsequent neoplasms among childhood cancer survivors. Study Details The study involved data on 5-year survivors of childhood cancers diagnosed...
ASTRO Updates Guideline on Radiation Therapy for High-Grade Diffuse Glioma
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) focuses on the use of radiation therapy for adults with World Health Organization (WHO) grade 4 diffuse gliomas, a category that includes some of the most common and most aggressive primary brain tumors. The...
FDA Approves Taletrectinib for ROS1-Positive Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved the oral next-generation ROS1 tyrosine kinase inhibitor (TKI) talectrectinib (Ibtrozi) for the treatment of adults with ROS1-positive locally advanced or metastatic non–small cell lung cancer (NSCLC). Investigators reported that the agent has ...
Novel Dual-Target CAR T-Cell Therapy May Slow Growth of Recurrent Glioblastoma
An investigational dual-target chimeric antigen receptor (CAR) T-cell therapy approach could slow tumor growth in patients with recurrent glioblastoma, according to new findings presented by Bagley et al at the 2025 ASCO Annual Meeting (Abstract 102) and simultaneously published in Nature ...
Manmeet Singh Ahluwalia, MD, MBA, FASCO, on Liquid Biopsy in Glioblastoma
Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcranial MR-guided microbubble-enhanced transcranial focused ultrasound for increasing blood circulating...
Gabapentin May Extend Survival in Patients With Glioblastoma
Investigators have found that the antiseizure/pain drug gabapentin may be associated with improved survival in patients with glioblastoma, according to a recent study published by Bernstock et al in Nature Communications. Background With about 12,000 new cases diagnosed annually in the United...
Activity of ROS1 TKI in NSCLC
In a pooled analysis of the phase II TRUST-I and TRUST-II trials reported in the Journal of Clinical Oncology, Pérol et al found that the oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib was highly active in ROS1-positive advanced or metastatic ...
Pediatric ALL or Lymphoblastic Lymphoma: Reduced Induction Dexamethasone and High-Dose Methotrexate
In a UK phase III trial (UKALL 2011) reported in the Journal of Clinical Oncology, Kirkwood et al found that a shorter duration of induction dexamethasone did not reduce steroid-related toxicity and that high-dose methotrexate (HDM) did not reduce central nervous system (CNS) relapse among patients ...
Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases
Patients with melanoma and lung cancer who have brain metastases may experience severe inflammatory reactions after receipt of immunotherapy drugs combined with radiation therapy, according to a recent study published by Vaios et al in JAMA Network Open. Study Methods and Results In this study,...
FDA Approves Bevacizumab Biosimilar
The U.S. Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne), a biosimilar to bevacizumab (Avastin), for intravenous use. Bevacizumab-nwgd is a recombinant humanized monoclonal antibody and a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks...
Firefighters May Face Higher Risk of Gliomas Associated With Gene Mutations Caused by Haloalkanes
Among patients with gliomas, gene mutations related to exposure to certain chemical compounds may be more common in firefighters than in those with other occupations, according to a recent study published by Cannataro et al in Cancer. Background Certain chemical compounds have been known to cause...
Novel Nanoliposome Radiotherapeutic May Enhance Survival in Patients With Glioblastoma
The investigational drug formulation rhenium (Re)-186 obisbemeda (RNL-186) may extend survival in patients with glioblastoma, according to a recent study published by Brenner et al in Nature Communications. Background Glioblastoma is the most common primary brain tumor in adult patients. The median ...
Clonal and Subclonal Pathogenic Alterations at Diagnosis in High-Risk Neuroblastoma
In a Children’s Oncology Group (COG) study reported in the Journal of Clinical Oncology, Berko et al identified the spectrum and clinical significance of clonal and subclonal pathogenic alterations in high-risk neuroblastoma. Study Details The study involved use of a focused high-risk neuroblastoma ...
Postradiotherapy Survival in Patients With Glioblastoma Multiforme and Low-Grade Gliomas
Investigators may have uncovered how radiotherapy affects survival in patients with glioblastoma multiforme and low-grade glioma, according to a recent study published by Veviorskiy et al in Aging. The findings highlighted key biological differences between these cancer types. Background...
Final Results of LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC
As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, and colleagues, final results of the registrational phase I/II LIBRETTO-001 trial showed continued benefit of the RET receptor tyrosine...
Survival Outcomes in Patients With ERBB2-Positive Metastatic Breast Cancer With CNS Involvement
In a retrospective cohort study from Memorial Sloan Kettering Cancer Center, which was reported in JAMA Network Open, Ferraro et al found that patients with ERBB2 (formerly HER2 or HER2/neu)-positive breast cancer and central nervous system (CNS) metastases only vs concomitant extracranial...
Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL
A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), including those with isolated or combined extramedullary...
Does Brain MRI Surveillance Benefit Asymptomatic Patients With Stage IV Breast Cancer?
Researchers have found that asymptomatic brain metastases may be more common in patients with stage IV breast cancer than previously understood, according to a recent study published by Ahmed et al in Neuro-Oncology. The findings suggest that physicians may need to reconsider current screening...
AALL1731 Trial: Adding Blinatumomab to Standard Chemotherapy Improves Outcomes in Pediatric B-Cell ALL
Results of a phase III study suggest that the addition of the immunotherapy agent blinatumomab—a bispecific T-cell engager targeting CD19—to standard chemotherapy may help to prevent relapse in more children with B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer,...
Extent and Impact of Primary MMRD in Gliomas Among Children and AYAs
In a cohort study reported in The Lancet Oncology, Negm et al found that primary mismatch repair deficiency (MMRD) was associated with poor outcomes in children, adolescents, and young adults with gliomas. Study Details In the study, clinical and molecular data were collected from children,...
Effects of Obesity on Survival Outcomes Following Cancer Diagnosis in Pediatric Patients
Pediatric patients with cancer who have obesity at the time of diagnosis may face an elevated risk of mortality, according to a recent study published by Sassine et al in Cancer. Study Methods and Results In the retrospective study, investigators examined data from the Cancer in Young People in...
New Study Identifies Genes That Could Be Implicated in Glioblastoma in Adulthood
Researchers have discovered of a new type of stem cell in the brain that could lead to the development of more effective treatments in adult patients with glioblastoma, according to a recent study published by Wang et al in Nature. The finding could help explain how adult brain cells take advantage ...
Unresectable Locally Advanced KRAS-Mutant NSCLC
This is Part 3 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the management of a patient with unresectable locally...
Temozolomide Plus Radiotherapy for Low-Grade Gliomas
Based on the phase III E3F05 trial, conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), the combination of radiation therapy and temozolomide appeared to be more effective than radiotherapy alone in the treatment of low-grade gliomas. The trial followed 172 patients for more than 10...
Challenges, Potential of Mesenchymal Stem Cells in Cancer Immunotherapy
Investigators have assessed the potential role of mesenchymal stem cells in cancer treatment in a new review published by Minev et al in Oncotarget. Study Overview and Implications The investigators found that mesenchymal stem cells can naturally target tumors and deliver therapeutic agents...
Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1–Associated Plexiform Neurofibroma
In a phase IIb trial (ReNeu) reported in the Journal of Clinical Oncology, Moertel et al found that the CNS-penetrant small molecule MEK1/2 inhibitor mirdametinib showed activity in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma (NF1-PN). Study...
